| |
| |
|
| Insider
Information: |
Soni Manmeet Singh |
| Relationship: |
Chief Operating Office... |
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,982,092 |
|
|
Indirect Shares
|
83 |
|
|
| Direct
Value |
$12,286,568 |
|
|
|
Indirect Value
|
$11,948 |
|
|
| Total
Shares |
2,982,175 |
|
|
| Total
Value |
$12,298,516 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
7
|
|
Stock
price went up :
|
1
|
7
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
7.0
|
| Percentage
Gain/Loss : |
 29.4%
|
539.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pharmacyclics Inc |
PCYC |
Chief Financial Officer |
2015-05-26 |
0 |
2013-04-30 |
0 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Chief Financial Officer |
2017-07-25 |
0 |
2018-07-10 |
83 |
Premium* |
|
|
Arena Pharmaceuticals Inc |
ARNA |
Director |
2020-06-17 |
5,902 |
2018-12-14 |
0 |
Premium* |
|
|
Reata Pharmaceuticals Inc |
RETA |
COO, CFO and President |
2023-09-26 |
0 |
2020-08-14 |
0 |
Premium* |
|
|
Summit Therapeutics Inc |
SMMT |
Chief Operating Office... |
2023-10-13 |
2,976,190 |
2023-10-13 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
44 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PCYC |
Pharmacyclics Inc |
VP, Corporate Controller |
• – – |
2013-04-30 |
4 |
A |
$52.24 |
$12,799 |
D/D |
245 |
245 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Executive VP, Finance |
• – – |
2013-10-31 |
4 |
A |
$52.24 |
$8,411 |
D/D |
161 |
406 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
32,406 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-04-30 |
4 |
A |
$80.39 |
$16,400 |
D/D |
204 |
32,610 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
38,610 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-10-31 |
4 |
A |
$80.93 |
$81 |
D/D |
1 |
38,611 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-11-13 |
4 |
OE |
$61.60 |
$61,600 |
D/D |
1,000 |
39,611 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2014-11-13 |
4 |
S |
$141.44 |
$141,442 |
D/D |
(1,000) |
38,611 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
60,611 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-03-03 |
4 |
D |
$216.77 |
$560,121 |
D/D |
(2,584) |
58,027 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-03-11 |
4 |
S |
$254.15 |
$6,124,507 |
D/D |
(24,098) |
58,027 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-03-11 |
4 |
OE |
$61.60 |
$1,808,849 |
D/D |
24,098 |
82,125 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-03-13 |
4 |
S |
$254.88 |
$870,756 |
D/D |
(3,416) |
54,611 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-05-26 |
4 |
D |
$261.25 |
$14,107,500 |
D/D |
(54,000) |
873 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Financial Officer |
• – – |
2015-05-26 |
4 |
D |
$261.25 |
$228,071 |
D/D |
(873) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2 |
2 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2017-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
11 |
13 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2018-01-17 |
4 |
A |
$0.00 |
$0 |
I/I |
6 |
19 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
28 |
47 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Financial Officer |
• – – |
2018-07-10 |
4 |
A |
$0.00 |
$0 |
I/I |
36 |
83 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,650 |
1,825 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,654 |
6,304 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2019-06-14 |
4 |
AS |
$55.82 |
$68,022 |
D/D |
(1,217) |
5,087 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,446 |
7,533 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-15 |
4 |
AS |
$60.12 |
$79,779 |
D/D |
(1,327) |
6,206 |
0 |
% |
|
44 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
